PATENT CLAIM ANALYSIS

Application Number: 15522969
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-04
Patent Classification: ["514", "252030"]

Abstract:
Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant Aβ peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L′ is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.

Claim (Index 19):
The compound of any one of  claims 1 - 18 , wherein R 2  is unsubstituted C 1 -C 5  alkyl.

Metadata:
- Claim Count in Document: 6.0
- Percentile: 91.0
- Lexical Diversity: 1.77358
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15421258', '14775483', '14992396', '14550528', '13806692']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7852532837160933
- 35 USC 102 Novelty (BERT): 0.5444595353232632
- Combined Prediction Score: 0.7611739088768102
- Mean Citation Score: 364.897392
- Max Citation Score: 378.66806
- Similarity Product: 279.26422292629366

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test